Ionis wins FDA approval to expand Tryngolza into severe hypertriglyceridemia, a far larger market than its rare FCS launch, with peak US sales seen topping $3B.
Ionis landed an FDA approval on Wednesday that will greatly expand its commercial opportunity for Tryngolza.
The antisense drug may now be used to treat …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Ionis scores transformational FDA label expansion for Tryngolza
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk - Ionis Pharmaceuticals
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
FDA approves Tryngolza to reduce triglycerides, pancreatitis risk in hypertriglyceridemia
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
Severe Hypertriglyceridemia Drug Approved to Reduce Triglycerides, Pancreatitis Risk
Lilly's retatrutide has been offered to a single person via 'compassionate use' program
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
Lilly exec says MFN will affect company's obesity pill launch strategy in Europe: report
After 35 years engaged in the research and development of pharmaceutical products, Ionis began marketing its drugs for the first…
Ionis wins FDA approval for Tryngolza in severe hypertriglyceridemia and signs a Recordati licensing deal for zilganersen
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute…
The FDA has approved olezarsen as the first and only therapy, alongside diet, to lower triglycerides and acute pancreatitis risk…
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at…
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
